Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection (BEYOND)
Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection: The BEYOND Double-Blind Randomized Clinical Trial
Sponsor: Hellenic Institute for the Study of Sepsis
A PHASE2 clinical study on Clostridioides Difficile Infection and Clostridioides Difficile Infection Recurrence, this trial is completed. The trial is conducted by Hellenic Institute for the Study of Sepsis and has accumulated 10 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Mar 2026 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jun 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2022 — Jun 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — Oct 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hellenic Institute for the Study of Sepsis
For direct contact, visit the study record on ClinicalTrials.gov .